Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies.
Lucila N KerbauyNancy D MarinMecit KaplanPinaki P BanerjeeMelissa M Berrien-ElliottMichelle Becker-HapakRafet BasarMark FosterLuciana Garcia MeloCarly C NealEthan McClainMay DaherAna Karen Nunez CortesSweta DesaiFrancesca Wei Inng LimMayela Carolina MendtTimothy SchappeLi LiHila ShaimMayra ShanleyEmily L EnsleyNadima UpretyPamela WongEnli LiuSonny O AngRong CaiVandana NandivadaVakul MohantyQi MiaoYifei ShenNatalia BaranNatalie Wall FowlkesKen ChenLuis Muniz-FelicianoRichard E ChamplinYago L NietoJoachim KochMartin TrederWolfgang FischerOswaldo Keith OkamotoElizabeth J ShpallTodd A FehnigerKatayoun RezvaniPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
We identify AFM13 as a promising combination with cytokine-activated adult blood or cord-blood NK cells to treat CD30+ hematologic malignancies, warranting clinical trials with these novel combinations.